Viridian Therapeutics, Inc.\DE
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
During the three months ended September 30, 2026, the following directors or officers of the Company adopted or terminated a “Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K:
| Name and Title | Plan Action | Plan Adoption Date | Expiration Date | Number of Shares to be Sold under Plan |
|---|---|---|---|---|
| Thomas Beetham, Chief Operating Officer | Adoption | 8/12/2026 | 12/17/2027 | 60,000 |
| Seth Harmon, Chief Financial Officer | Adoption | 8/21/2026 | 8/18/2027 | 67,574 |
| Stephen Mahoney, Chief Executive Officer | Adoption | 8/12/2026 | 6/15/2027 | 70,000 |
| Jennifer Tousignant, Chief Legal Officer | Adoption | 8/19/2026 | 8/31/2027 | 21,132* |
*In addition to the listed number of shares to be sold, the Rule 10b5-1 trading arrangement also includes an undetermined number of shares that may be purchased by Ms. Tousignant under the Company’s 2025 ESPP.
During the three months ended September 30, 2026, none of the Company’s officers or directors adopted orterminated any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.